In 2024, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved evaluation applications for biopharmaceuticals that were subjected to technical reviews. The approvals included *** therapeutic Investigational New Drug (IND) applications, ** prophylactic IND applications, and *** New Drug Applications (NDA).Â
An approved IND application is the prerequisite for a drug product to enter its clinical trial phase, and a drug can only enter the market for general use after its NDA application is approved by the regulatory body.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
National Medical Products Administration. (March 18, 2025). Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2024, by type of application [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 31, 2026, from /statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. "Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2024, by type of application." Chart. March 18, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 31, 2026. /statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. (2025). Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2024, by type of application. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 31, 2026. /statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration. "Number of Approved Evaluation Applications for Biopharmaceuticals Subjected to Technical Reviews in China in 2024, by Type of Application." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 18 Mar 2025, /statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
National Medical Products Administration, Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2024, by type of application ÌÇÐÄÆƽâ°æ, /statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/ (last visited July 31, 2026)
Number of approved evaluation applications for biopharmaceuticals subjected to technical reviews in China in 2024, by type of application [Graph], National Medical Products Administration, March 18, 2025. [Online]. Available: /statistics/1319961/china-number-of-biopharmaceutical-evaluation-applications-approved-by-type/
